• Figen Aslan, Gürhan Güney, Ayla Solmaz Avcıkurt, Mine Islimye Taşkın, and Gizem Akkaş Akgün.
• Department of Gynecology, Balikesir University Medical Faculty, Cagis Yerleskesi, Bigadic Yolu 17. km Altieylul, Balikesir, Turkey.
• J Coll Physicians Surg Pak. 2020 Apr 1; 30 (4): 373-378.

ObjectiveTo determine whether there is a relationship between endometrium cancer and the oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A).Study DesignA descriptive study.Place And Duration Of StudyBalıkesir University Medical Faculty Hospital, Balıkesir, Turkey, from January 2013 to July 2018.MethodologyCIP2A was studied immunohistochemically and molecularly in paraffin blocks. The correlation between CIP2A expression and different endometrial pathologies were evaluated. In addition, the relationship between CIP2A expression in tumor tissue and clinicopathological prognostic parameters and also between Ki67, P53, HER2 with CIP2A expression were investigated.ResultsA higher expression of CIP2A was found in endometrium cancer tissues compared to normal endometrial tissues. In addition, CIP2A expression according to molecular and immunohistochemical results was associated with significant poor prognostic factors such as FIGO Stage, FIGO Grade, cervical involvement, myometrial invasion and HER2 positivity.ConclusionCIP2A could be a promising and therapeutic target in endometrium cancer. Invention of the complex connections of CIP2A with other oncoproteins may lead to amazing and interesting developments in both early diagnosis and treatment. Key Words: CIP2A, Endometrium cancer, Expression, Oncoprotein.

11 keywords...

hide…